Key Highlights
- An executive action from President Trump instructed federal agencies to accelerate psychedelic drug evaluations, sparking a sector-wide rally.
- ENVB shares skyrocketed over 160% during Monday’s session, positioning it among the top performers in psychedelic biotechnology.
- The administration pledged $50 million for ibogaine studies, targeting the Schedule I substance’s potential in treating PTSD.
- Compass Pathways (CMPS) climbed 26.1%, AtaiBeckley (ATAI) advanced 28.1%, and GH Research (GHRS) surged approximately 20%.
- RBC’s Brian Abrahams characterized the directive as “a substantial step towards diminishing regulatory risk” across the industry.
The psychedelic therapeutics sector experienced a dramatic surge Monday following President Trump’s weekend executive action directing federal health authorities to expedite approval pathways for psychedelic-derived medications. Enveric Biosciences (ENVB) emerged as the session’s standout performer, closing with gains exceeding 160% — a remarkable jump for a company carrying a modest $3.43 million market capitalization.
Enveric Biosciences, Inc., ENVB
The executive order took a sweeping approach, avoiding specific company mentions while issuing comprehensive instructions to the FDA and associated regulatory bodies to streamline bureaucratic barriers surrounding psychedelic therapy authorizations. This broad mandate proved sufficient to ignite trading activity across virtually every publicly-traded entity in the sector.
AtaiBeckley (ATAI) soared 28.1% during premarket trading. Compass Pathways (CMPS) registered a 26.1% increase. Definium Therapeutics (DFTX) rose 14.6%. GH Research (GHRS) posted gains of 19.7%. The momentum swept through the space with remarkable velocity.
Administration Commits $50M to Ibogaine Studies
Alongside the regulatory directive, Trump announced a $50 million allocation dedicated to ibogaine investigation. This psychoactive alkaloid, extracted from the African Tabernanthe iboga shrub, remains classified under Schedule I designation domestically — indicating no currently accepted medical application under federal law.
This financial commitment represents a notable policy evolution regarding mental health interventions, with particular emphasis on post-traumatic stress disorder treatment. Preliminary clinical evidence suggests ibogaine holds therapeutic potential for PTSD sufferers, particularly within veteran populations.
Compass CEO Kabir Nath publicly applauded the executive measure, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” RBC analyst Brian Abrahams reinforced this sentiment, characterizing the action as “a substantial step towards diminishing regulatory risk” throughout the psychedelic treatment landscape.
ENVB’s explosive price movement arrived with notable timing. The company had just completed a $5 million private placement mere days prior — a capital raise that actually exceeded the firm’s total market valuation at execution. The transaction involved 2,222,223 shares priced at $2.25 apiece, accompanied by dual warrant series carrying a $2.00 per share strike price.
Development Pipeline and Intellectual Property Developments
The company’s primary therapeutic candidate, EB-003, engages 5-HT2A and 5-HT1B receptor systems and targets psychiatric along with neurological disorders. Recently disclosed mechanistic findings demonstrated EB-003’s capacity to trigger dual signaling cascades associated with antidepressant and anxiolytic therapeutic outcomes.
ENVB additionally secured U.S. patent protection encompassing its EVM301 molecular series, which incorporates EB-003, while simultaneously obtaining Canadian trademark registrations across five proprietary marks including “Enveric” and “Next Generation Mental Health.”
Should both warrant tranches from the private placement reach full exercise, the organization stands to generate an additional $8.9 million in gross capital.
Monday’s stock performance — surpassing 160% — captured both the favorable regulatory environment created by the executive order and the recently secured financing that extended the company’s operational timeline precisely as this catalyst materialized.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
